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Introduction
Radiotherapy has long been in clinical use for cancer treat-
ment. The DNA of tumors and healthy cells is injured by ion-
izing radiation, resulting in complex biochemical reactions, 
prolonged abnormal cell function, and, eventually, cellular 
death. Beams of ionizing photons such as X-rays or gamma-
rays have been used for treating various types of cancer. Cur-
rently, the widely available X-ray beam therapy (XRT) is con-
sidered as the “conventional” radiation treatment method in 
clinical practice.
Charged particle beam therapy (i.e., particle therapy) has 
been emerging clinically as a branch of radiotherapy from the 
late twentieth century [1]. The initial clinical implementations 
were conducted at the University of Tsukuba and Loma Lin-
da University, which started clinical centers for proton thera-
py in 1983 and 1990, respectively [2,3] and the National Insti-
tute of Radiological Sciences in Japan, which treated patients 
with the carbon ion therapy in 1994 [4]. Particle therapy with 
protons and heavier charged particles has significant physical 
and biological advantages over conventional therapy [5], thus 
allowing them to potentially achieve more effective tumor 
control while sparing the surrounding normal tissues. 
Proton therapy is being used worldwide, including in two 
centers in Korea, but carbon ion therapy is available only in 
a few countries, namely, Germany, Italy, Austria, Japan, and 
China [6]. Carbon ion therapy facilities in Korea are also 
under construction in two centers [7], and we expect that 
particle therapy will be of more use to many cancer patients 
in the near future. However, non-radiological oncologists or 
even trainees in radiation oncology are unfamiliar with par-
ticle therapy, compared with conventional radiotherapy. In 
this paper, we introduce the basics of physical and biological 
characteristics of particle therapy for oncologists and focus on 
some recent issues, especially proton and carbon ion thera-
pies.
Definition and Clinical Aspects of Particle 
Therapy
 
1. Definition of particle therapy
Particle therapy for cancer treatment is a form of external 
beam radiotherapy using protons, neutrons, or other heavier 
ions (e.g., helium or carbon ions). The type of a specific par-
ticle therapy is generally based on the particles to generate 
beams for therapy. 
2. Particle therapy in clinics
Physically, particle beams yield the benefit of precise dose 
localization, compared with X-rays. Particle beams deposit 
sharply increased energy at the last part and a very small 
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dose in the tissue over the beam. This results in a decreased 
radiation dose delivered to normal tissues, compared to that 
in XRT, at the entry site of the radiation field and beyond the 
target area. For these reasons, radiation oncologists would 
expect radiation-induced morbidity from normal tissue 
damage to be smaller. It might be possible to deliver higher 
ablative doses of charged particles to the tumor area while 
reducing damage to the normal tissue. This property is par-
ticularly attractive for inoperable case or tumors adjacent to 
critical structures. Recently, some clinical studies reported 
that proton therapy might be beneficial not only for tumors 
in adjacent organs but also to counteract the systemic com-
plications from radiotherapy. Less low-dose exposure dur-
ing proton therapy might affect the level of lymphocytes, 
which are regarded as a marker of immunity and therapeutic 
responses [8]. In a phase II randomized study, proton therapy 
reduced the rate of severe radiation-induced lymphopenia 
in glioblastoma patients from 39% to 14%, compared with 
XRT [9]. Additionally, retrospective studies have supported 
this result [10]. Particle therapy has the potential to reduce 
another complication, secondary cancer. A recent study of 
450,000 patients conducted using the Chinese national data-
base reported that the risk of secondary cancer during pro-
ton therapy had an odds ratio of 0.31 compared with that in 
intensity-modulated radiotherapy [11]. In a Japanese study, 
the risk of secondary malignancy after carbon ion therapy for 
prostate cancer was compared to that after photon radiother-
apy or surgery alone [12]. The results revealed that carbon 
ion therapy conferred significantly lower risk of developing 
secondary malignancy, with a hazard ratio of 0.80, than pho-
ton radiotherapy. The risk of secondary malignancy in car-
bon ion therapy was also not increased compared to that of 
surgery alone. Clinical studies for particle therapy have been 
gradually increasing, mostly based on proton therapy, or car-
bon ion therapy. Although there were fewer studies on other 
heavy particle therapies, centers using helium ion therapies 
have been showing good results [13,14]. 
Physics in Particle Therapy
1. Physical characteristics of particle therapy
Physically, charged particle beams deposit energy along 
their paths when traveling in the body and exhibit a unique 
depth-dose distribution, termed the “Bragg peak” (Fig. 1). 
This special physical characteristic distinguishes particle 
therapy from X-ray. The particles deposit most of their 
energy in the final millimeters of their trajectory as they slow 
down. This results in a steep and localized peak of dose. 
Photon beams or X-rays do not have a Bragg peak and, thus, 
deliver the maximum dose to the tissues upon entry, follow-
ing which, they are gradually attenuated as they pass through 
the body. Nevertheless, a substantial dose is still delivered 
deep inside the body. This is because X-rays are a form of 
electromagnetic radiation that has no mass or charge; there-
fore, they easily pass through the body and deposit energy 
along the whole length of their path. Due to the nature of X-
rays, multi-focus beams such as intensity-modulated radio-
therapy are usually needed to irradiate deep-seated tumors 
with external beam X-rays with useful conformity. Because 
of the multi-focus beams, normal tissues around the target 
receive low doses of radiation. Consequently, compared with 
intensity-modulated radiotherapy, particle therapy can pro-
duce steeper dose gradients and a more conformal dose dis-
tribution without increasing the dose delivered to the normal 
tissue, using a smaller number of beams, as shown in Fig. 2. 
As shown in Fig. 1, the Bragg peak used in particle therapy 
is too sharper and thinner than that used in conventional 
therapy. To utilize the particle beams in radiation therapy, it 
is necessary to achieve broadening of the beam, termed the 
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Fig. 1.  (A) Depth-dose distributions for photons, protons, and carbon ions. (B) A spread-out Bragg peak of a carbon ion beam (bold line) 
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“spread-out Bragg Peak (SOBP),” to extend the uniform dose 
region to treat tumors of different depths. SOBP is the sum of 
several individual Bragg peaks at staggered depths. 
The physical characteristics vary according to the type 
of particle. From the point of view of dose distribution, the 
beam quality depends on its energy spread, range strag-
gling, and lateral sharpness, all being smaller in magnitude 
with increasing particle mass. For example, carbon ion beam 
shows a higher physical dose concentration with a narrow 
penumbra compared to proton beam, as shown in Fig. 3. 
Another difference between heavier ions and protons is the 
fragmentation mechanism. Compared with that of protons, 
fragmentation of carbon ions (e.g., boron, beryllium, lithium, 
and helium) occurs because of nuclear interactions between 
the atoms of the irradiated tissue. The energy of the fragmen-
tation is deposited beyond the range of the carbon ions in the 
so-called tail region (Fig. 1). The biological effect of this frag-
mentation is small because the tail contains only fragments 
with a low atomic number; nevertheless, this tail region of 
carbon ion beams should be checked through the radiation 
planning system if organs at risk surround the target.
2. Beam delivery systems for particle therapy 
Accelerators are one of the major devices used in radio-
therapy that produce and shape an electric field to accelerate 
charged particles. In conventional XRT, a single-pass-type 
accelerator (i.e., linear accelerator) is generally used to 
accelerate electron beams through the linear path. Unfortu-
nately, due to the heavier mass of charged particles compared 
to that of electrons, the small size of the linear accelerator 
cannot produce a sufficient electric field for particle therapy. 
At present, the available option for heavier particle therapy 
involves efficient reuse of the electric field using circular (or 
multi-pass-type) accelerators (e.g., cyclotrons, synchrotrons, 
synchrocyclotrons) instead of a linear accelerator to reach the 
required energy for clinical use of particle beams.
The first particle accelerator was built in the early 1950s as 
a synchrocyclotron [15,16]. The first patient was treated in 
1957 using proton beams at the Lawrence Berkeley National 
Laboratory [17-19]. As of December 2020, 57 cyclotrons, 41 
synchrotrons, and 13 synchrocyclotrons have been installed 
in various particle therapy centers for clinical use (e.g., 250 
MeV for protons and 440 MeV/u for carbon ions) [20]. In 
general, these circular accelerators require large space for 
installation compared to conventional linear accelerators. 
Nevertheless, during the treatment process, the time the 
accelerator operates is much shorter than the time for patient 
setup or beam alignment in the treatment room. Consequent-
ly, most institutes operate several treatment rooms per accel-
erator to save time and optimize treatment schedules. 
Particle therapy can be delivered using two delivery sys-
tems: (1) a beam scattering method using a passive system 
and (2) a beam scanning method using an active system. In 
the passive system, the narrow peaks are swept over a wide 
area by a peak filter to create an SOBP, corresponding to the 
target volume size. This method simultaneously uses a band 
modulator, a collimator, and a compensator. In the active sys-
tem, the peak position is moved within the target by varying 
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Fig. 2.  Screenshot of plan comparison between carbon ion therapy (A) and conventional X-ray intensity-modulated radiotherapy (B). Note 
that carbon ion beams can produce steeper dose gradients and a more conformal dose distribution without increasing the dose delivered 
to the normal tissue, with a smaller number of beams. 
A B
Fig. 3.  Comparison of the lateral penumbra between protons 
and carbon ions. The penumbra of a carbon beam is much sharp-
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the beam energy in the accelerator or by changing the beam’s 
penetration using absorbers at a dose sufficient to conform 
precisely to the target volume [21]. Fig. 4 schematically dem-
onstrates the concepts of passive scattering beam and active 
scanning beam delivery systems used in particle therapy.
3. Issues in beam delivery for particle therapy 
In particle therapy, an important issue, based on the 
respective physical properties, is the range uncertainty in the 
beam path length. Characterized by steep dose gradients, 
anatomical changes (including organ movements) might 
cause an important issue for the robustness of the clinical tar-
get coverage. To avoid these uncertainties, charged particle 
therapy should also include the verification of plan robust-
ness with respect to anatomical changes. Some of the robust 
optimization methods are distributional robustness, proba-
bilistic robustness, worst case robustness, and voxel-wise 
worst-case robustness [22].  
Another issue for active beam delivery systems is the 
interplay effect. The interplay effect is a dynamic character-
istic of the particle beam that combines body motions (such 
as breathing) and spatiotemporal difference during beam 
delivery, resulting in a disagreement between the planned 
dose and the delivered dose [23]. During the early days of 
proton therapy for passive beam delivery or fixed target 
organs, this was not much of an issue. However, in active 
beam delivery or the scanning-type of beam in advanced sys-
tems, this should be considered for moving the target organs 
such as the lung and liver. As the worst-case scenario, missing 
of the target organs due to the interplay effect is a concerning 
issue for radiation oncologists, despite setting up everything 
perfectly. Nevertheless, researchers reported that the effect 
could be reduced through multiple fractionation schedules 
[24]. A study on hepatocellular carcinoma confirmed that 
proton therapy using pencil-beam scanning with approxi-
mately 10 fractions showed no significant effect in terms of 
local control compared with proton therapy using passive 
scattering [25]. We can make more robust plans to consider 
uncertainties such as organ motions by increasing the target 
margin, or by using planned algorithms to optimize robust-
ness. Also, motion control via abdominal compression or 
breath-holding might be effective in some patients. Another 
strategy is real-time tracking of beam delivery. Some tracking 
methods to tackle the effects of such interplay have been sug-
gested. The most advanced method is “beam gating,” where 
the irradiation is gated by a pertinent signal generated from 
the patient. Another system under investigation is the “fast 
rescanning delivery,” where beam delivery to a homogene-
ous target irradiation is restored by multiple scans, lead-
ing to averaging of the dose inhomogeneity introduced by 
interplay effects. The last technique is “target tracking,” 
which aims at real-time tracking of the target motion with 
the scanning beam. Tracking is the most demanding option 
because it requires real-time adjustment of not only the lat-
eral beam position but also the beam energy. 
Cancer Res Treat. 2021;53(3):611-620
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Biology in Particle Therapy 
1. Linear energy transfer and relative biological effective-
ness of particle beams
To explain the radiobiological effect of particle therapy, it 
is necessary to first define two concepts, namely, linear ener-
gy transfer (LET) and relative biological effectiveness (RBE) 
[21]. When radiation is absorbed by the biological material, 
ionizations and excitations occur. These are not randomly 
distributed but tend to be localized along the tracks of indi-
vidual charged particles in a pattern depending on the type 
of radiation involved. The LET is the energy transferred per 
unit length of the track. Usually, high-LET beams are defined 
as accelerated atomic nuclei with an atomic number great-
er than 2 due to the different biological effects. Carbon ion 
(atomic number of 6) beams are defined as high-LET beams. 
Proton beams are considered intermediary in this regard. 
Their LET is larger than that of photon beams; however, they 
still belong to the “radiobiological” group of low LET. Low-
LET radiation demonstrates a uniform, sparse spatial distri-
bution of ionization in cells, while high-LET particles bring 
about dense ionization by depositing energy in the medium, 
thereby demonstrating higher biological effects. Notably, 
carbon ions show lower LET in normal tissue and higher 
LET in the target tissue, yielding a greater therapeutic benefit 
than other ions, such as oxygen, and protons; oxygen shows 
relatively high LET in normal tissues, while proton beams 
show low LET in both tumor and normal tissue areas (Fig. 5).
The amount or quantity of radiation is expressed in terms 
of the absorbed dose, a physical quantity measured in gray 
(Gy). However, even when physical doses are equal, differ-
ent types of radiation do not produce equivalent biological 
effects. For example, 1 Gy of carbon ion beams produces a 
greater biological effect than 1 Gy of X-rays. When compar-
ing different types of radiations, it is common to use X-rays 
as the standard. The concept of RBE was introduced to com-
pare the biological effect of different radiation types with 
that of X-rays. The RBE of a test radiation r is defined as the 
D250/Dr ratio, where D250 and Dr are the doses of 250-kV X-
rays and of test radiation, respectively, required for equal 
biological effect [26]. For example, suppose we are measuring 
the RBE of specific particles compared with that of 250-kV 
X-rays based on the lethality of some specific cells. Groups of 
cells are irradiated by a range of X-ray doses; parallel groups 
are irradiated by a range of specific particle beam doses. At 
the end of the observation, the dose that results in the death 
of half of the cells in a group turns out to be 9 Gy for X-rays 
and 3 Gy for the particles. The RBE of the particles is then 
equal to 3, i.e., the ratio of 9 Gy to 3 Gy. 
LET and RBE are closely associated with each other. High-
LET radiations usually lead to stronger biological effects 
than low-LET radiations. RBE is a function of LET. RBE ini-
tially increases approximately linearly as LET increases. At 
higher LET, the increase in RBE slows, eventually reaching a 
turning point after which RBE decreases, because of energy 
wasting (Fig. 6). In proton therapy, a generic RBE of 1.1 has 
been widely used [27], irrespective of dose-modifying fac-
tors such as fractionation, tissue type, or radiation quality. 
An RBE value of 1.1 is a constant scaling factor used along 
the pathway of the proton, including the normal tissues and 
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Fig. 5.  Comparison of dose-averaged linear energy transfer 
(LETd) between protons and carbon ions in water. The LETd for 
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Fig. 6.  Diagram illustrating why high-linear energy transfer 
(LET) radiation has the greatest relative biological effectiveness 
(RBE) for cell death, mutagenesis, or oncogenic transformation. 
High-LET radiation is most likely to produce a double-strand 
break from one track for an administered absorbed dose. Beyond 
the point at which the RBE reaches a peak, energy is wasted  
because the ionizing events are closer than the diameter of the 
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tumors; therefore, it does not provide benefits in terms of 
an increased therapeutic window. However, the actual RBE 
of the proton beam is known to vary with LET, particularly 
at the distal part of the range of the monoenergetic proton 
beam penetration, where LET increases. Thus, it should be 
avoided to locate critical normal structures at that distal end 
of the proton beams. In addition, experimental RBE of proton 
beams is calculated differently depending on the type of cell 
lines [28]. It was thought that the variance of RBE occurred 
according to the characteristics of the radiation repair pro-
cess, and DNA damage response signaling showed different 
activation durations related to RBE. Thus, the invariant RBE 
value used currently has been criticized, and optimal ways 
to replace the standard RBE value are being investigated 
[29,30]. 
In contrast, the RBE of carbon ions is not a constant value 
but a function of position within the treatment beam. RBE 
tends to increase as the particle penetrates deeper into the 
target lesion. The depth-dose profile for each SOBP field was 
designed to yield a constant biological effect within the SOBP 
area by compensating for the increase in LET along its path. 
Deeper regions in the SOBP, where the LET is high, receive 
a lower physical dose; in contrast, shallower regions, where 
the LET is low, receive a higher physical dose (Fig. 7). Fur-
thermore, at the entry site (normal tissue), the RBE value is 
lower than that in the SOBP, which eventually widens the 
therapeutic window of carbon ion therapy. In addition, sev-
eral other radiation dose-modifying factors such as fractiona-
tion, tissue type, and radiation quality are taken into account 
to determine the RBE.
The biological RBE was determined by a specific biologi-
cal system and a biological endpoint and then scaled to the 
specific irradiation conditions of patients to obtain a “clini-
cal RBE” (Fig. 7). The clinical RBE describes the ratio of pre-
scribed absorbed doses of a photon to a high-LET irradiation, 
which are believed to result in clinically equivalent results. 
The RBE thus obtained was validated using the tumor con-
trol probability from clinical data. Because of the complex-
ity of RBE of carbon ion therapy, a biomathematical model 
is needed to consider the inconstant biological effect appro-
priate to calculate the RBE in treatment planning. Radiation 
oncologists have tried to improve the models to reach a “uni-
versal” definition of RBE-weighted dose, although it is not 
yet feasible to fully simulate the underlying biological pro-
cesses. The use of in vitro data for RBE models is also a major 
weakness because the biological effectiveness is affected by 
general patient condition and the tumor microenvironment. 
2. Biological characteristics of high-LET radiations
Solid tumors are often characterized by hypoxia. Acute 
(perfusion-limited) hypoxia is caused by temporary distur-
bance in perfusion, resulting in fluctuating microvascular 
oxygen supply. Chronic hypoxia arises due to the over-pro-
liferation of cancer cells with poor vasculature. The increased 
distance between cells and the nearest blood vessel limits 
oxygen diffusion from tumor microvessels into the sur-
rounding tissue. Tumor hypoxia is known to correlate with 
poor prognosis in cancer patients [31]. Low-LET radiation 
mostly causes DNA damage due to the presence of free radi-
cals, which is enhanced by oxygen. Hence, tumor hypoxia 
has been considered to be one of the major mechanisms of 
radioresistance in cancer cells. The ratio of doses to hypoxic 
and normoxic tissues (oxygen enhancement ratio [OER]) can 
be close to 3 with low-LET radiation such as gamma-rays 
and X-rays, making tumor control by radiation difficult in 
the presence of hypoxia [32]. One method to overcome this 
obstacle in radiotherapy with low-LET radiation is multiple 
fractionations. Multiple fractionations allow for the supply 
of oxygen to the surviving, previously hypoxic volumes, 
between fractions, through a process termed reoxygenation. 
In contrast, high-LET radiation strikes the DNA molecule 
directly and disrupts the molecular structure. This extensive 
damage is less influenced by oxygen levels. The OER is lower 
in high-LET beams. When high-LET radiation is delivered, 
the hypoxic tumor sites tend to not be affected by oxygen 
levels, demonstrating similar radiosensitivity. Therefore, 
heavy ion beams can have a better effect on hypoxic tumors 
such that the need for fractionation for reoxygenation is 
diminished. Fractionated irradiation is a basic concept of 
radiotherapy leading to improved therapeutic ratio. Various 
biological effects account for the benefits of fractionated irra-
Cancer Res Treat. 2021;53(3):611-620
Fig. 7.  Physical, biological, and clinical depth-dose distributions 
for carbon beam spread-out Bragg peak (SOBP). The biological 
model was obtained using an in vitro model of a human sali-
vary gland tumor cell line. The physical dose×relative biological  
effectiveness (RBE) is supposed to be constant within the SOBP. 
Note that the physical dose line is curved within the SOBP area. 
Accordingly, the RBE within the SOBP area is not a constant val-
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diation: (1) repair, (2) repopulation, (3) redistribution, and (4) 
reoxygenation, known as the “4Rs.” Repair and repopulation 
promote the recovery of damaged normal tissue, and redis-
tribution and reoxygenation promote tumor control. The 4Rs 
are an important issue in conventional XRT, although they 
are of little importance for high-LET radiations. For example, 
sublethal damage repair, which promotes cell survival, is not 
as obvious in high-LET beams as in low-LET ones. The effect 
of high-LET radiation is uniform irrespective of the cell cycle, 
while the effect of low-LET radiation is affected by the cell 
cycle. The 4Rs’ effects in particle beams are small enough to 
neglect these factors. For these reasons, carbon ion therapy 
requires a lower number of fractions, shorter than XRT. 
3. Special topics according to biology in particle therapy
Radiogenomics is the study of the link between germline 
or somatic genetic variations and the clinical variability 
observed in response to radiotherapy. The Radiogenomics 
Consortium, which included 133 institutions from 33 coun-
tries as of April 2019 [33], has worked on patient samples by 
using single-nucleotide polymorphisms (SNPs) to perform 
genome-wide association studies (GWAS). SNPs are DNA 
sequence variations that occur when a single nucleotide 
within a gene locus is altered. The principle of a GWAS is 
to genotype between 300,000 and 1,000,000 tag SNPs, which 
represent most of the known common variations within the 
genome. The associations between SNPs and radiation-relat-
ed toxicity have been identified and validated by the con-
sortium, although the effects are not yet clinically actionable. 
For example, in prostate cancer, the TANC1 locus at 2q24.1 
was found to be associated with overall urinary and bowel 
toxicity after radiation [34]; the KDM3B locus at 5q31.2 was 
associated with increased urinary frequency after radiation 
[35]; and the DNAH5 locus at 5p15.2 was associated with uri-
nary retention after radiation [35]. 
The radiogenomic data of the response of mammalian 
cells to charged particles, predominantly protons and carbon 
ions, is less mature compared with X-ray exposures. Whether 
patients who receive particle therapy have different biomark-
ers of normal tissue toxicity than those who receive conven-
tional radiotherapy is an open question. Although radiation 
generally activates the genes associated with inflammatory 
pathways, DNA repair, and cell cycle progression, the spe-
cific genes activated by X-rays, proton, and carbon ions can 
be different [36]. Efforts are underway to establish cohorts of 
patients with prostate cancer treated at the National Institute 
of Radiological Sciences with carbon ion therapy or proton 
therapy for radiogenomic studies [37]. Among the results of 
experimental studies of gene expression after exposure to 
carbon ions, the downregulation of genes involved in motil-
ity due to carbon ion therapy is of particular interest [38,39], 
which are, in contrast, generally upregulated by X-ray expo-
sure [40-42]. Carbon ion therapy appears to suppress migra-
tion, invasion, and metastasis of cancer cells [43,44] and does 
not lead to the induction of hypoxia-inducible factor-1 [45] 
and stem cell factor expression [39], both of which are asso- 
ciated with angiogenesis. Reduced tumor cell migration 
and invasion and reduced angiogenesis may be some of the 
major benefits of carbon ion therapy. However, the impact 
of these molecular signatures requires validation in animal 
models and in human studies. 
In addition to dosimetric analyses, tests for germline and 
tumor genetic variants can be incorporated into clinical 
decision-making regarding particle therapy. For example, 
patients who carry the NF1 gene mutation are radiosensitive 
and predisposed to a number of cancers. NF1 mutations can 
be used as indicators in patients receiving proton therapy 
to reduce the risk of secondary radiation-related malignan-
cies [46]. Furthermore, the identification of radioresistance to 
low-LET radiation using the GWAS approach can improve 
the selection of patients eligible for carbon ion therapy; how-
ever, this approach needs to be validated in prospective clini-
cal studies.
Another special issue with particle therapy is immuno-
therapy. Immunotherapy has recently emerged as a prom-
ising set of new cancer treatments. Immune checkpoint 
blockade, which increases antitumor immunity by block-
ing inhibitory checkpoints, has gained an important place 
in the treatment of various types of cancer. However, the 
overall response rates with immune checkpoint blockade 
monotherapy are modest. For example, the response rates 
of melanoma after ipilimumab and pembrolizumab or 
nivolumab therapy range from 11% to 19% [47,48] and 33% 
to 44% [48-50], respectively. Thus, novel strategies that aug-
ment systemic immune responses will be potentially critical 
in the curative management of the disease. The addition of 
radiotherapy to immunotherapy for patients with predomi-
nantly widespread metastases has gained substantial inter-
est. Radiation-induced cancer cell death results in the release 
of pro-inflammatory signals such as damage-associated 
molecular patterns  danger signals and inflammatory cyto-
kines, thereby triggering the innate immune system to acti-
vate tumor-specific T cells. Radiation also has an effect on 
the tumor microenvironment, by promoting the infiltration 
of activated T cells, and can overcome some of the barriers to 
tumor rejection [51]. The advantages and outcomes of com-
bined particle therapy with immunotherapy are still open for 
investigation. Preclinical studies support the immunogenic 
potential of proton therapy and suggest that proton therapy 
may actually have a wider range of immunogenic applica-
tions than photon therapy. For example, in vitro studies have 
reported that protons mediated a greater increase in the 
Hwa Kyung Byun, Physical and Biological Aspects of Particle Therapy
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expression of calreticulin on the cell surface than photons, 
increasing cross-priming to cytotoxic T lymphocyte killing 
[52]. 
Photon and carbon ion therapies induce different DNA 
damage and repair pathways, and this difference is based 
on the differential biological response to low- and high-LET 
beams. Depending on LET and dose, ionizing radiation 
causes a variety of different DNA lesions, including single- 
and double-strand breaks, DNA-protein cross-links, and 
DNA base damages [53]. This variation can be important 
because programmed death-ligand 1 expression in can-
cer cells is upregulated in response to DNA double-strand 
breaks [54]. Because carbon ion therapy is performed in few 
sites worldwide, only limited experimental information is 
currently available. The typical endpoints of these experi-
ments include the abscopal effect, defined as a reaction of 
the organism’s cells that had not been directly exposed to 
irradiation, which causes regression of the non-irradiated 
tumors and the growth of distal metastases [55]. Matsunaga 
et al. [56] reported that carbon ion therapy administered to 
a poorly immunogenic squamous cell carcinoma cell line 
induces reduction of tumor formation after secondary tumor 
challenge at the contralateral site in mouse models. It has 
been shown that carbon ion therapy induces systemic antitu-
mor immunity. Combined carbon ion therapy and dendritic 
cell injection generated more prominent cytolytic activity 
than carbon ion therapy alone. Ando et al. [57] reported that 
a combination treatment of carbon ion therapy and intrave-
nous dendritic cell administration enhances the suppression 
of lung metastases. 
Conclusion
Particle therapy involves better dose distribution based 
on the Bragg peak, physically. Biologically, it shows higher 
LET and RBE, which is expected to be powerful from a clini-
cal point of view. These properties enable the administration 
of higher radiation doses to the tumors while subjecting the 
normal organs to a reasonably low dose, thus widening the 
therapeutic ratio. Because of the lack of clinical trials, it is 
not clearly demonstrated whether carbon ion therapy has 
superior clinical benefits over other radiotherapy modalities. 
Although further comparison studies are needed, conduct-
ing randomized controlled trials comparing carbon ion ther-
apy, proton therapy, and XRT seems to be difficult, mostly 
because of the differences in treatment costs and patients’ 
preferences. Nevertheless, we expect that the superior bio-
logical and physical aspects of carbon ion therapy will lead 
to meaningful clinical benefit in cancer patients. Another 
uncertainty remains concerning the RBE. Currently, the con-
stant RBE value of 1.1 for proton therapy is being criticized; 
thus, further investigation is required to determine the opti-
mal RBE and its association with LET and dose. The RBE of 
carbon ion therapy has to be calculated by biomathematical 
models in treatment planning, which—in spite of all valida-
tion efforts—still involve significant sources of uncertainty. 
Molecular biological research using highly advanced tech-
nologies such as multi-omics or the effects of the combination 
of immunotherapy has to be incorporated into the particle 
therapy research field. By resolving unsolved issues regard-
ing the physical and biological properties of particle therapy, 
we believe that the future of particle therapy is promising.
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